BMSplus – the portal for health care professionals

Genitourinary Cancer

August 2024 - OPDIVO^® is now approved in combination with cisplatin/gemcitabine chemotherapy for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma with PD-L1 tumor expression ≥1%.

More information

Gastrointestinal Cancer

March 2024 – OPDIVO^® (nivolumab) in combination with chemotherapy containing oxaliplatin and fluoropyrimidine is indicated for the first-line treatment of adult patients with inoperable, locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, and distal oesophageal adenocarcinoma with Combined Positive Score (CPS) PD-L1 expression ≥ 10.

More information

Melanoma

Februar 2024 – OPDUALAG^® (nivolumab/relatlimab) is now reimbursed for the first-line treatment of adults with metastatic melanoma with PD-L1 < 1% expression.

www.spezialitaetenliste.ch

More information

Melanoma

November 2023 – Q4W 480 mg dosing with OPDIVO^® (nivolumab) is approved in all melanoma indications.

Q4W dosing is approved for all Nivolumab monotherapy as well as monotherapy maintenance after Nivolumab + Ipilimumab combination treatment in melanoma.

More information

Melanoma

October 2023 – OPDIVO^® (nivolumab) as monotherapy is indicated for the adjuvant treatment of adults with completely resected Stage IIB or IIC melanoma.

More information

Large B-Cell Lymphoma

September 2023 – Swissmedic approved BREYANZI^® (lisocabtagene maraleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL) or primary mediastinal large B-cell lymphoma (PMBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

BREYANZI^®
▼ This drug is subject to additional monitoring. For further information, please refer to the information for healthcare professionals on swissmedicinfo.ch.

More information